Disease overview

Alterations

124

Molecular (A)

100

Clinical (B–E)

Direct drugs

229

Via biomarker

Natural agents

Natural products

Merged ranked

294

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent; moderate-severe adult AD: <15% spontaneous clearance at 5 years

Best-intervention remission

Dupilumab (anti-IL-4Rα): 51% IGA 0/1 (clear/almost clear) at 16 weeks in SOLO trials; tralokinumab (anti-IL-13): 38% clear/almost clear; baricitinib (JAK1/2i): 16% EASI-100 (complete clearance) at 16 weeks; upadacitinib (JAK1i): 28-40% EASI-100; near-complete clearance now achievable for most patients

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — most patients managed with topical steroids for decades without biologic assessment; biologics available since 2017 but reach only a fraction of eligible patients

Primary barrier

access/practice

Barrier detail: Dupilumab approved 2017 but still not first-line in most health systems due to cost ($36,000/year); step therapy requirements force patients through years of topical steroids and immunosuppressants first; racial disparities in specialist access and biologic prescribing

Last SoC change: 2022-2023 — JAK inhibitors (upadacitinib, baricitinib) and tralokinumab added; lebrikizumab approved 2023; dupilumab since 2017; prior standard (topical steroids, tacrolimus, cyclosporine) essentially unchanged since 1980s-2000s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004980

Alterations

124 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormality of metabolism/homeostasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Allergic rhinitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Asthma	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Atopic dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Cataract	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Conjunctivitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Dry skin	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Eczematoid dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Facial erythema	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Flexural lichenification	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Food intolerance	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ichthyosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Infra-orbital fold	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Keratoconus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Keratosis pilaris	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pallor	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pruritus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Recurrent skin infections	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ACOXL acyl-CoA oxidase like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACTL9 actin like 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADO 2-aminoethanethiol dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AFF1 ALF transcription elongation factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGO2 argonaute RISC catalytic component 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AHI1 Abelson helper integration site 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AHR aryl hydrocarbon receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANKRD55 ankyrin repeat domain 55	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARRDC1 arrestin domain containing 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AUCinf of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Adverse Events	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BACH2 BACH transcriptional regulator 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BATF3 basic leucine zipper ATF-like transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BHLHE40 basic helix-loop-helix family member e40	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BLTP1 bridge-like lipid transfer protein family member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CARD11 caspase recruitment domain family member 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCDC80 coiled-coil domain containing 80	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD200R1 CD200 receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD207 CD207 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHRM3 cholinergic receptor muscarinic 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CIART circadian associated repressor of transcription	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CREB5 cAMP responsive element binding protein 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF2RB colony stimulating factor 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP24A1 cytochrome P450 family 24 subfamily A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Cmax of Abrocitinib Metabolite (PF-06471658/M1) Following the Administration of Abrocitinib 1×200 mg Tablet With or Without Famotidine 40 mg in Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
D2HGDH D-2-hydroxyglutarate dehydrogenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DOK2 docking protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DSC1 desmocollin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EHMT1 euchromatic histone lysine methyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETS1 ETS proto-oncogene 1, transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGF2 fibroblast growth factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FKBP1A FKBP prolyl isomerase 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLG filaggrin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOSL2 FOS like 2, AP-1 transcription factor subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FOXP1 forkhead box P1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA3 GATA binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLB1 galactosidase beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMSD histocompatibility minor serpin domain containing	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRH1 histamine receptor H1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRNR hornerin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL13 interleukin 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL18R1 interleukin 18 receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL18RAP interleukin 18 receptor accessory protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1RL1 interleukin 1 receptor like 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2 interleukin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL22 interleukin 22	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL22RA2 interleukin 22 receptor subunit alpha 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL3 interleukin 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL31RA interleukin 31 receptor A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL4R interleukin 4 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6R interleukin 6 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL7R interleukin 7 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
INPP5D inositol polyphosphate-5-phosphatase D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF4 interferon regulatory factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Investigator Global Assessment	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK3 Janus kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KDELR2 KDEL endoplasmic reticulum protein retention receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP12 matrix metallopeptidase 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFILZ NFIL3 like basic leucine zipper	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NLRP10 NLR family pyrin domain containing 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Number of Participants With Treatment Emergent Adverse Events (TEAE)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PDCD1 programmed cell death 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4A phosphodiesterase 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4B phosphodiesterase 4B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4C phosphodiesterase 4C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4D phosphodiesterase 4D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PLXNC1 plexin C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PON1 paraoxonase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPIA peptidylprolyl isomerase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRKCQ protein kinase C theta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRORP protein only RNase P catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PRR5L proline rich 5 like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RARA retinoic acid receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RARB retinoic acid receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RARG retinoic acid receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RGS14 regulator of G protein signaling 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RPRD2 regulation of nuclear pre-mRNA domain containing 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RUNX3 RUNX family transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRA retinoid X receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRB retinoid X receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RXRG retinoid X receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SATB1 SATB homeobox 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SERPINB7 serpin family B member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC6A2 solute carrier family 6 member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC7A10 solute carrier family 7 member 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC9A4 solute carrier family 9 member A4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SUOX sulfite oxidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TACR1 tachykinin receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TAGAP T cell activation RhoGTPase activating protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TESPA1 thymocyte expressed, positive selection associated 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFRSF11A TNF receptor superfamily member 11a	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFRSF4 TNF receptor superfamily member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFRSF6B TNF receptor superfamily member 6b	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFSF18 TNF superfamily member 18	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNFSF4 TNF superfamily member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TRAF3 TNF receptor associated factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TRIB1 tribbles pseudokinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TYK2 tyrosine kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZBTB10 zinc finger and BTB domain containing 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZNF217 zinc finger protein 217	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ZNF652 zinc finger protein 652	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
METOPROLOL	Small molecule	Approved	Strong	100	5 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT05607901 — A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone (COMPLETED) PHASE2 NCT00691262 — Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis (COMPLETED) PHASE3 NCT01782729 — An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis (COMPLETED) PHASE4 NCT00475605 — A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (TERMINATED) NCT07437534 — Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (NOT_YET_RECRUITING) PHASE4 NCT00523952 — Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients (COMPLETED) PHASE3 NCT00667160 — Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis (COMPLETED) PHASE4 NCT06241118 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (RECRUITING) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	6 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04965233 — Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes (WITHDRAWN) NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLIOQUINOL Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT01429701 — Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVOTHYROXINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLCELLULOSE Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT05719649 — The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial (UNKNOWN) NA CT.gov search · Cochrane · PubMed	DGIdb	—
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICLOSAMIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NICOTINE Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NITAZOXANIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OMEPRAZOLE Repurposing	Small molecule	Approved	Strong	95	5 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
PHENAZOPYRIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
RESVERATROL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ROMIPLOSTIM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAPINAROF Repurposing	Small molecule	Approved	Strong	95	8 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT05014568 — Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (COMPLETED) PHASE3 NCT02564055 — A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) (COMPLETED) PHASE2 NCT07265479 — A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (RECRUITING) PHASE3 NCT05186805 — Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis (COMPLETED) PHASE2 NCT01098734 — Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream (COMPLETED) PHASE2 NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (NOT_YET_RECRUITING) PHASE4 NCT00837551 — Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis (COMPLETED) PHASE1, PHASE2 NCT05032859 — Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) (COMPLETED) PHASE3 Published literature Clinical trial publication Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials (Journal of the American Academy of Dermatology, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
THIABENDAZOLE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AGANIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMLITELIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BENZOCAINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEPOTASTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE VALERATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETIRIZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CIMETIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLEMASTINE FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLIOQUINOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COMEKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIFAMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIFELIKEFALIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUSIDATE SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GENTAMICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVARMACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVARMACITINIB SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOTIFEN FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OATMEAL, COLLOIDAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PAC-14028	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
POLYMYXIN B SULFATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCATINLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
STAPOKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOLNAFTATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRADIPITANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UREA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFIMKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMMONIUM TRICHLOROTELLURATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTROQUINONOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASTEGOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATUZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AWD-12-281	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARZOLVOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMPIKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENRALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIMOSIAMOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMX-010	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BOSAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRANEBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIPOTRIENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMLIPIXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMOTESKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CENDAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPHALEXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIS-UROCANIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBAMAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIHOMO-GAMMA-LINOLENIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DNK333	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETRASIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FB-825	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEVIPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEZAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOCINONIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALVOKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-1070806	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GUSACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-870086	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HALOBETASOL PROPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDREBORMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFIDANCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITEPEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-39758979	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KT-474	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LACTULOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEPZACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIGELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIRENTELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOTAMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNSEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTIKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAPRACORAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEPOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOSEDIPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MUFEMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCANKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCTENIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMIGANAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMPEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORISMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALMIDROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGCANTRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITRAKINRA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNICARBATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZPEGALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSIPTOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROVAZOLAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
S-777469	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERTACONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILVER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOQUELITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPESOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURODEOXYCHOLIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAZORLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMTOKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEZEPELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILREKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIMAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TORUDOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIMETHOPRIM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UCENPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UDIFITIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEHICLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BOTULINUM TOXIN TYPE A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAFFEINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CERDULATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLOBETASOL PROPIONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLONIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIPHENHYDRAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HONEY	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELRILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OVATODIOLIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-5212372	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGN-846	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM HYPOCHLORITE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VIXARELIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WARFARIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ABROCITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANTIMONY	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZATHIOPRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BILASTINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHOLESTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CORTISONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CRISABOROLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROMOLYN SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DELGOCITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESLORATADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIFLUCORTOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIMETHINDENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOXEPIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINASTINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUOCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTICASONE PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCYRRHIZINATE DIPOTASSIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE BUTYRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
JUNIPER TAR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEBRIKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOCETIRIZINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOCETIRIZINE DIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MILPECITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MUCOPOLYSACCHARIDE POLYSULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEMOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLOPATADINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIMECROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIPERAZINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RESOMELAGON ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RETAPAMULIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAPINAROF	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TIRNOVETMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRALOKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
UPADACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
AGANIRSEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AMLITELIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BENZOCAINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEPOTASTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE DIPROPIONATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BETAMETHASONE VALERATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BIFIDOBACTERIUM SPP.	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CETIRIZINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CIMETIDINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLEMASTINE FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLIOQUINOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
COMEKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIFAMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIFELIKEFALIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUSIDATE SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GENTAMICIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVARMACITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IVARMACITINIB SULFATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOTIFEN FUMARATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OATMEAL, COLLOIDAL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PAC-14028	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
POLYMYXIN B SULFATE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE ACETATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCATINLIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
STAPOKIBART	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TOLNAFTATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRADIPITANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE HEXACETONIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UREA	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ACLOPROXALAP	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADRIFORANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AFIMKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMMONIUM TRICHLOROTELLURATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANTROQUINONOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
APREMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ASTEGOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATUZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AWD-12-281	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BARZOLVOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMPIKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BENRALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERMEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BIMOSIAMOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMX-010	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BOSAKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BRANEBRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCIPOTRIENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CALCITRIOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMLIPIXANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAMOTESKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CENDAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CEPHALEXIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CIS-UROCANIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CO-TRIMOXAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COBAMAMIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DIHOMO-GAMMA-LINOLENIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DNK333	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOXYCYCLINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ETRASIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FB-825	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEVIPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEZAKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FLUOCINONIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GALVOKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GSK-1070806	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GUSACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GW-870086	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HALOBETASOL PROPIONATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HUMAN IMMUNOGLOBULIN G	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IDREBORMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IFIDANCITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ITEPEKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
IVERMECTIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
JNJ-39758979	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
KT-474	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LACTULOSE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEPZACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIGELIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LIRENTELIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOTAMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUNSEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTIKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAPRACORAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MEPOLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOMETASONE FUROATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MOSEDIPIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MUFEMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALTREXONE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCANKITUG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OCTENIDINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMIGANAN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
OMPEKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ORISMILAST	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PALMIDROL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGCANTRATINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PITRAKINRA	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PREDNICARBATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
REZPEGALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RILZABRUTINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RISANKIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSE BENGAL SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROSIPTOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ROVAZOLAC	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
S-777469	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SERTACONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILVER	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM CHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SOQUELITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SPESOLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TAURODEOXYCHOLIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TELAZORLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMTOKIBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEZEPELUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TILREKIMIG	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TIMAPIPRANT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TORUDOKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOZORAKIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TRIMETHOPRIM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UCENPRUBART	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UDIFITIMOD	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
USTEKINUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEHICLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ANAKINRA	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BOTULINUM TOXIN TYPE A	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CAFFEINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CERDULATINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLOBETASOL PROPIONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CLONIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CURCUMIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DIPHENHYDRAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GLUTAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HONEY	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE ACETATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INFLUENZA VIRUS VACCINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELATONIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MELRILIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
METOPROLOL	Small molecule	Phase I	Emerging	35	5 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
MIDAZOLAM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OMEPRAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OVATODIOLIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
PF-5212372	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
REGN-846	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
RUXOLITINIB PHOSPHATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SODIUM HYPOCHLORITE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Phase I	Emerging	35	8 trials View evidence Registry trials NCT05607901 — A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone (COMPLETED) PHASE2 NCT00691262 — Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis (COMPLETED) PHASE3 NCT01782729 — An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis (COMPLETED) PHASE4 NCT00475605 — A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (TERMINATED) NCT07437534 — Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (NOT_YET_RECRUITING) PHASE4 NCT00523952 — Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients (COMPLETED) PHASE3 NCT00667160 — Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis (COMPLETED) PHASE4 NCT06241118 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (RECRUITING) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
VIXARELIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
WARFARIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ABROCITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ADALIMUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ANTIMONY	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
AZATHIOPRINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
BILASTINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CHOLESTEROL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CORTISONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CRISABOROLE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CROMOLYN SODIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DELGOCITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESLORATADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DESONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE SODIUM PHOSPHATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIFLUCORTOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DIMETHINDENE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DOXEPIN HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
EPINASTINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FEXOFENADINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUOCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FLUTICASONE PROPIONATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GLYCYRRHIZINATE DIPOTASSIUM	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE BUTYRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
INFLUENZA A VIRUS, SPLIT VIRION	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
IPRATROPIUM BROMIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
JUNIPER TAR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LACTOBACILLUS ACIDOPHILUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEBRIKIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOCETIRIZINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LEVOCETIRIZINE DIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LIDOCAINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MILPECITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
MUCOPOLYSACCHARIDE POLYSULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
NEMOLIZUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
OLOPATADINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIMECROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PIPERAZINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROMETHAZINE HYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
QUINAZOLINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RESOMELAGON ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RETAPAMULIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAPINAROF	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TIRNOVETMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRALOKINUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
UPADACITINIB	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
VITAMIN B12	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ZINC SULFATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMPHETAMINE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CAFFEINE Repurposing via AHR	Small molecule	Approved	Strong	95	6 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04965233 — Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes (WITHDRAWN) NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLIOQUINOL Repurposing via AHR	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT01429701 — Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIAZEPAM Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPIRUBICIN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
FLUMAZENIL Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing via AHR	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing via ADO	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AFF1	Small molecule	Approved	Strong	95	4 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVOTHYROXINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHYLCELLULOSE Repurposing via AHR	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT05719649 — The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial (UNKNOWN) NA CT.gov search · Cochrane · PubMed	DGIdb	—
METOPROLOL Repurposing via AFF1	Small molecule	Approved	Strong	95	5 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via AFF1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NICLOSAMIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NICOTINE Repurposing via AFF1	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
NITAZOXANIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
NORFLOXACIN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via AFF1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
OLANZAPINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
OMEPRAZOLE Repurposing via AHR	Small molecule	Approved	Strong	95	5 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
PHENAZOPYRIDINE HYDROCHLORIDE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
PHENYTOIN Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PIPERINE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
PRAZOSIN Repurposing via AFF1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
RESVERATROL Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ROMIPLOSTIM Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SIROLIMUS Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SULBACTAM Repurposing via AFF1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via AFF1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT05607901 — A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone (COMPLETED) PHASE2 NCT00691262 — Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis (COMPLETED) PHASE3 NCT01782729 — An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis (COMPLETED) PHASE4 NCT00475605 — A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (TERMINATED) NCT07437534 — Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (NOT_YET_RECRUITING) PHASE4 NCT00523952 — Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients (COMPLETED) PHASE3 NCT00667160 — Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis (COMPLETED) PHASE4 NCT06241118 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (RECRUITING) PHASE3 CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAPINAROF Repurposing via AHR	Small molecule	Approved	Strong	95	8 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT05014568 — Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (COMPLETED) PHASE3 NCT02564055 — A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) (COMPLETED) PHASE2 NCT07265479 — A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis (RECRUITING) PHASE3 NCT05186805 — Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis (COMPLETED) PHASE2 NCT01098734 — Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream (COMPLETED) PHASE2 NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (NOT_YET_RECRUITING) PHASE4 NCT00837551 — Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis (COMPLETED) PHASE1, PHASE2 NCT05032859 — Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) (COMPLETED) PHASE3 Published literature Clinical trial publication Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials (Journal of the American Academy of Dermatology, 2024) CT.gov search · Cochrane · PubMed	DGIdb	—
TAZOBACTAM Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
THIABENDAZOLE Repurposing via AHR	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
TROGLITAZONE Repurposing via AFF1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DARAPLADIB Repurposing via AFF1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via AFF1	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALPRENOLOL Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via AFF1	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

82 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Probiotics Natural product Cochrane review Maternal probiotic supplementation and offspring health: an umbrella re… Cochrane review An Umbrella Review on the Prevention of Skin Diseases: Do Specific Nutr… Cochrane review From the Cochrane Library: Dietary Supplements for Established Atopic E…	Probiotic	Approved	Emerging	16	8 trials 16 Cochrane 11 Meta-analysis 19 Trial pubs 19 RCT View evidence Registry trials NCT03822624 — Study to Evaluate the Use of a Probiotic in SCORAD Reduction in Young Patients With Atopic Dermatitis (UNKNOWN) NA NCT06035835 — Probiotics and Breastmilk Decrease Risk of Atopic Dermatitis in Premature Infants (COMPLETED) NCT05443490 — Clinical Trial to Evaluate the Effect of a Probiotic Mixture in the Treatment of Atopic Dermatitis in Children (TERMINATED) NA NCT03157284 — Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis (COMPLETED) NA NCT02519556 — Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children (COMPLETED) PHASE4 NCT03863418 — Probiotic Lactobacillus Rhamnosus GG for Pediatric Atopic Dermatitis (UNKNOWN) NA NCT05719649 — The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial (UNKNOWN) NA NCT00378300 — The Effects of Probiotics in Atopic Dermatitis (WITHDRAWN) NA Published literature Cochrane review Maternal probiotic supplementation and offspring health: an umbrella review with re-analysis of systematic reviews and meta-analyses (Frontiers in nutrition, 2026) Cochrane review An Umbrella Review on the Prevention of Skin Diseases: Do Specific Nutrients Play a Protective Role? (Preventive nutrition and food science, 2026) Cochrane review From the Cochrane Library: Dietary Supplements for Established Atopic Eczema (JMIR dermatology, 2022) Cochrane review Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials (American journal of clinical dermatology, 2022) Cochrane review What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies (Clinical and experimental dermatology, 2020) Systematic review The Influences of Oral Probiotics on the Immunometabolic Response During Pregnancy and Lactation: A Systematic Review (Nutrients, 2025) Systematic review Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics (Expert opinion on investigational drugs, 2024) Clinical trial publication The Role of Infant Gut Microbiota Modulation by Perinatal Maternal Probiotic Intervention in Atopic Eczema Risk Reduction (Neonatology, 2025) Clinical trial publication Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2023) Clinical trial publication Postnatal probiotics and allergic disease in very preterm infants: Sub-study to the ProPrems randomized trial (Allergy, 2020) Clinical trial publication Probiotics in the prevention of eczema: a randomised controlled trial (Archives of disease in childhood, 2014) Clinical trial publication Interaction of NPSR1 genotypes and probiotics in the manifestation of atopic eczema in early childhood (Allergologia et immunopathologia, 2014) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, GreenMedInfo	GreenMedInfo
Lactobacillus Natural product Cochrane review An Umbrella Review on the Prevention of Skin Diseases: Do Specific Nutr… Cochrane review Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention… Systematic review What's new in atopic eczema? An analysis of systematic reviews publishe…	Probiotic	Approved	Emerging	16	8 trials 2 Cochrane 1 Meta-analysis 15 Trial pubs 15 RCT View evidence Registry trials NCT03042624 — Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial (UNKNOWN) NA NCT06035835 — Probiotics and Breastmilk Decrease Risk of Atopic Dermatitis in Premature Infants (COMPLETED) NCT06474728 — Effects of an Emollient Containing Postbiotic Saccharomyces and Lactobacillus on Pediatric Atopic Dermatitis (COMPLETED) NA NCT03157284 — Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis (COMPLETED) NA NCT02519556 — Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children (COMPLETED) PHASE4 NCT03863418 — Probiotic Lactobacillus Rhamnosus GG for Pediatric Atopic Dermatitis (UNKNOWN) NA NCT05719649 — The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial (UNKNOWN) NA NCT00325273 — Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonatal Period (COMPLETED) PHASE3 Published literature Cochrane review An Umbrella Review on the Prevention of Skin Diseases: Do Specific Nutrients Play a Protective Role? (Preventive nutrition and food science, 2026) Cochrane review Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials (American journal of clinical dermatology, 2022) Systematic review What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies (Clinical and experimental dermatology, 2020) Clinical trial publication Probiotics in the prevention of eczema: a randomised controlled trial (Archives of disease in childhood, 2014) Clinical trial publication Predominant genera of fecal microbiota in children with atopic dermatitis are not altered by intake of probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07 (FEMS microbiology ecology, 2011) Clinical trial publication Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome (Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010) Clinical trial publication Cow's milk allergy is associated with changes in urinary organic acid concentrations (Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2010) Clinical trial publication Probiotic supplementation in the first 6 months of life in at risk Asian infants--effects on eczema and atopic sensitization at the age of 1 year (Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, GreenMedInfo	GreenMedInfo
Vitamin K Natural product Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil… Meta Analysis, Review Supplementation with around 1600 IU/daily of 25-hydroxyvitamin D result… Human Study Association of antioxidants and vitamin D level with inflammation in ch…	Nutraceutical	Phase I	Emerging	13	1 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil… Meta Analysis, Review Supplementation with around 1600 IU/daily of 25-hydroxyvitamin D result… Human Study Direct infant UV light exposure is associated with eczema and immune de…	Nutraceutical	Phase II	Emerging	10	8 trials View evidence Registry trials NCT05523986 — Vitamin D Treatment Effect for Atopic Dermatitis in Children (UNKNOWN) NA NCT01996423 — Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (COMPLETED) NA NCT02537509 — PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo (COMPLETED) PHASE2 NCT01234909 — Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis (TERMINATED) NCT04965233 — Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes (WITHDRAWN) NCT04354207 — Vitamin D and Its Receptor Gene Polymorphisms in Lithuanian, Latvian and Taiwanese Patients With Atopic Dermatitis and Asthma (UNKNOWN) NCT00879424 — Vitamin D Supplementation in Childhood Atopic Dermatitis (COMPLETED) NA NCT05913791 — Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin E Natural product Meta-analysis Dietary supplements for established atopic eczema Human Study Depressed levels of glutathione peroxidase are observed in patients wit… Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil…	Nutraceutical	Preclinical	Emerging	10	2 trials 1 Meta-analysis View evidence Registry trials NCT05913791 — Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema (UNKNOWN) NA NCT04445298 — Skin Barrier Assessment in Pregnancy and at Birth (UNKNOWN) Published literature Meta-analysis Dietary supplements for established atopic eczema (The Cochrane database of systematic reviews, 2012) CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Human Study Docosahexaenoic acid effect on prenatal exposure to arsenic and atopic… Human Study Maternal intake of n-6 polyunsaturated fatty acids, especially linoleic… Human Study Emollients containing coconut oil- and sunflower seed oil-derived fatty…	Nutraceutical	Preclinical	Emerging	10	1 trials 1 Trial pubs View evidence Registry trials NCT05913791 — Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin B12 Natural product Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil… Meta Analysis, Review Supplementation with around 1600 IU/daily of 25-hydroxyvitamin D result… Human Study Association of antioxidants and vitamin D level with inflammation in ch…	Nutraceutical	Preclinical	Emerging	10	1 trials View evidence Registry trials NCT00465699 — Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis (UNKNOWN) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin K Natural product Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil… Meta Analysis, Review Supplementation with around 1600 IU/daily of 25-hydroxyvitamin D result… Human Study Association of antioxidants and vitamin D level with inflammation in ch…	Nutraceutical	Phase I	Emerging	10	1 trials View evidence Registry trials NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Caffeine Natural product Maternal caffeine intake during pregnancy and risk of food allergy in y…	Food compound	Phase II	Emerging	9	6 trials View evidence Registry trials NCT03556592 — Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (COMPLETED) PHASE1 NCT04965233 — Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes (WITHDRAWN) NCT02647086 — Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) (COMPLETED) PHASE1 NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (COMPLETED) PHASE1 NCT05891119 — Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis (COMPLETED) EARLY_PHASE1 NCT04562116 — A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Selenium Natural product Meta Analysis, Review Selenium levels were associated with several skin diseases and the dise… Human Study Depressed levels of glutathione peroxidase are observed in patients wit…	Nutraceutical	Preclinical	Emerging	7	1 Cochrane 1 Meta-analysis View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Chamomile Natural product Evaluation of massage with essential oils on childhood atopic eczema Proof of efficacy of Kamillosan(R) cream in atopic eczema	Botanical	Preclinical	Emerging	7	2 RCT View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Turmeric Natural product	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Human Study Blackcurrant seed oil is well tolerated and transiently reduces the pre…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Moringa Natural product Human Study Advanced effect of Moringa oleifera bioconversion by Rhizopus oligospor…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Suramin Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Kaempferol Natural product Beer and beer compounds: physiological effects on skin health	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
8z-3,4',5-trimethoxystilbene Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Transtorine Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
3-methylcholanthrene Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Beta-Naphthoflavone Natural product Human Study TGF-beta in colostrum may prevent the development of atopic disease dur…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Fermented Foods and Beverages Natural product Human Study Advanced effect of Moringa oleifera bioconversion by Rhizopus oligospor… Human Study Fermented citrus juice containing heat-killed LP0132 had beneficial eff… Human Study Fermented food intake is associated with a reduced likelihood of atopic…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Homeopathic Medicine: All Natural product Human Study An over 50% improvement was reported in overall impression and in their… Human Study Evening primrose oil is a safe and effective medicine for Korean patien… Human Study Homeopathic treatment could be regarded as an effective choice for pati…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Plantarum Natural product Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r… Human Study Supplementation of Lactobacillus sakei in children with eczema-dermatit…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fucoidan Natural product Human Study "Fucoidan suppresses IgE production in peripheral blood mononuclea…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Ginseng (Korean) Natural product Human Study Energy-drink consumption is associated with asthma, allergic rhinitis,… Human Study Evening primrose oil is a safe and effective medicine for Korean patien… Human Study Korean red ginseng can be safely used as a health food to achieve clini…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Reuteri Natural product Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r… Human Study Supplementation of Lactobacillus sakei in children with eczema-dermatit…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Evening Primrose Oil Natural product Meta Analysis Evening primrose oil has therapeutic value in the treatment of atopic e… Human Study Evening primrose oil is a safe and effective medicine for Korean patien… Human Study Evening primrose oil might be effective in treating atopic dermatitis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Probiotics Natural product Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis A meta-analysis suggests a modest role for probiotics in pediatric atop… Meta Analysis The favorable effect of probiotic use in the prevention of atopic derma…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bifidobacterium Longum Natural product Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r… Human Study Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood… Human Study Prenatal and postnatal supplementation with a mixture of B. bifidum BGN…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Black Currant Natural product Human Study Black currant seed oil supplementation of mothers enhances IFN-γ and su… Human Study Blackcurrant seed oil is well tolerated and transiently reduces the pre…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Salivarius Natural product Human Study Changing of fecal flora and clinical effect of L. salivarius LS01 in ad… Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fig Natural product Human Study Efficacy and safety of fig leaf tea in adults with mild atopic dermatit… Human Study Fig fruit extract can be used instead of low potent corticosteroid in m…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Breast Milk Natural product Human Study Approximately 1 in every 3 patients with atopic eczema are positive for… Human Study Black currant seed oil supplementation of mothers enhances IFN-γ and su… Human Study Exclusive breastfeeding reduces the incidence of atopic dermatitis in c…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Purslane Natural product Human Study Purslane has some promising effects for reducing the extent and severit…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bee Venom Natural product Animal Study, Human: Case Report Bee venom acupuncture and herbal medicine for hand eczema. Human In Vitro These results suggest that apamin has therapeutic effect on atopic derm…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Myricetin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Sophora Flavescens Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Astaxanthin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Ginsenosides Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Sakei Natural product Human Study Supplementation of Lactobacillus sakei in children with eczema-dermatit… Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Oats Natural product Human Study A 1% colloidal oatmeal OTC cream is clinically effective for the manage… Human Study Oat and rice collodial grain suspensions may safely be used as an adjun…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Honey Natural product Human Study Anti-inflammatory properties of raw honey and its clinical applications… Human Study Manuka honey is potentially effective in the treatment of atopic dermat… Human In Vitro, Human Study The results of this preliminary study indicate a possible role of honey…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Fermentum Natural product Human Study Children with atopic dermatitis show clinical improvement after Lactoba… Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Water: Deep Sea Natural product Human Study Drinking deep-sea water restores mineral imbalance in atopic eczema/der… Human Study Free residual chlorine in bathing water reduces the water-holding capac… Human Study Those with atopic respiratory disease, although their skin appears norm…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bifidobacterium Lactis Natural product Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r… Human Study Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood… Human Study Prenatal and postnatal supplementation with a mixture of B. bifidum BGN…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coconut Oil Natural product Human Study Emollients containing coconut oil- and sunflower seed oil-derived fatty… Human Study Virgin coconut oil is superior to mineral oil in treating atopic dermat…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gamma-Linoleic Acid (GLA) Natural product Human Study Maternal intake of n-6 polyunsaturated fatty acids, especially linoleic… Human Study Gamma linolenic acid (GLA) may have therapeutic value in atopic eczema.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fos (Fructooligosaccharides) Natural product Human Study Lactobacillus salivarius plus fructo-oligosaccharide is superior to fru… Human Study Probiotic and prebiotic supplementation improves the symptoms of childr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Manuka Honey Natural product Human Study Anti-inflammatory properties of raw honey and its clinical applications… Human Study Manuka honey is potentially effective in the treatment of atopic dermat… Human In Vitro, Human Study The results of this preliminary study indicate a possible role of honey…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Rice Natural product Human Study Oat and rice collodial grain suspensions may safely be used as an adjun…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Essential Fatty Acids Natural product Human Study Maternal intake of n-6 polyunsaturated fatty acids, especially linoleic… Human Study Emollients containing coconut oil- and sunflower seed oil-derived fatty… Human Study Massage with essential oils has a therapeutic effect in childhood atopi…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bifidobacterium Bifidum Natural product Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r… Human Study Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood… Human Study Prenatal and postnatal supplementation with a mixture of B. bifidum BGN…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Honeysuckle Natural product Human Study Anti-inflammatory properties of raw honey and its clinical applications… Human In Vitro, Human Study The results of this preliminary study indicate a possible role of honey… Animal Study, In Vitro Study A homogeneous Lonicera japonica polysaccharide attenuates atopic dermat…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Seaweed: Brown Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Apigenin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Gotu Kola Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Flavonoids Natural product Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural P… Flavonoids as Potential Natural Compounds for the Prevention and Treatm…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Galactooligosaccharides Natural product Probiotics and prebiotic galacto-oligosaccharides in the prevention of…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chrysin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Gallic Acid Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Glycyrrhizin Natural product Tripterygium agents for the treatment of atopic eczema: A Bayesian anal…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Kimchi Natural product	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Naringenin Natural product	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Streptococcus Thermophilus Natural product Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Peanut Natural product Human Study 165 children with atopic dermatitis were studied, a higher number of se…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Borage Oil Natural product Human Study Borage oil is effective in treating atopic dermatitis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactobacillus Paracasei Natural product Human Study Children with atopic dermatitis show clinical improvement after Lactoba… Meta Analysis Lactic acid bacteria as probiotics reduce the risk for infantile eczema. Meta Analysis The mixed strain of Lactobacillus and Bifidobacterium can effectively r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Palmitoylethanolamide Natural product Human Study Efficacy of topical palmitoylethanolamide (Levagen+) for the management…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Kefir Natural product Human Study Homemade kefir consumption improves skin condition.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Indigo Naturalis Natural product Human Study Efficacy and safety of indigo naturalis oil extract (Lindioil ointment)… Human Study Indigo naturalis ointment is effective for treating mild to severe atop…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Lactococcus Lactis Natural product Human Study Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood… Human Study Prenatal and postnatal supplementation with a mixture of B. bifidum BGN… Human Study Probiotic and prebiotic supplementation improves the symptoms of childr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Colostrum Natural product Human Study TGF-beta in colostrum may prevent the development of atopic disease dur…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Transforming Growth Factor-Beta Natural product Human Study 165 children with atopic dermatitis were studied, a higher number of se… Human Study TGF-beta in colostrum may prevent the development of atopic disease dur… Human Study Wheat intolerance is a common causative factor in atopic dermatitis.	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Marshmallow Root Natural product Human Study The results of this pilot study showed that the efficacy of Althaea off…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
St. John's Wort Natural product Human Study Topical St. John's wort cream may improve Atopical Dermatitis.	Botanical	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Vitamin C: Intravenous Natural product Meta Analysis, Review Serum Vitamin D Level and efficacy of vitamin D supplementation in chil… Meta Analysis, Review Supplementation with around 1600 IU/daily of 25-hydroxyvitamin D result… Human Study Association of antioxidants and vitamin D level with inflammation in ch…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Coconut Oil: Topical Natural product Human Study Efficacy of topical palmitoylethanolamide (Levagen+) for the management… Human Study Emollients containing coconut oil- and sunflower seed oil-derived fatty… Human Study Indigo naturalis ointment is effective for treating mild to severe atop…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Elecampane Natural product Human In Vitro Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like r…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Chokeberry Natural product Animal Study, In Vitro Study Extract of wheatgrass and aronia mixture ameliorates atopic dermatitis-…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Wheat Grass Natural product Human Study Wheat intolerance is a common causative factor in atopic dermatitis. Animal Study, In Vitro Study Extract of wheatgrass and aronia mixture ameliorates atopic dermatitis-…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Atopic Dermatitis (Eczema)

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network